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Abstract
Background: During myocardial infarction reduced blood flow in the heart muscle results in cell death. These dying/dead
cells have been reported to bind several plasma proteins such as IgM and C-reactive protein (CRP). In the present study we
investigated whether fluid-phase complement inhibitor C4b-binding protein (C4BP) would also bind to the infarcted heart
tissue.
Methods and Findings: Initial studies using immunohistochemistry on tissue arrays for several cardiovascular disorders
indicated that C4BP can be found in heart tissue in several cardiac diseases but that it is most abundantly found in acute
myocardial infarction (AMI). This condition was studied in more detail by analyzing the time window and extent of C4BP
positivity. The binding of C4BP correlates to the same locations as C3b, a marker known to correlate to the patterns of IgM
and CRP staining. Based on criteria that describe the time after infarction we were able to pinpoint that C4BP binding is a
relatively early marker of tissue damage in myocardial infarction with a peak of binding between 12 hours and 5 days
subsequent to AMI, the phase in which infiltration of neutrophilic granulocytes in the heart is the most extensive.
Conclusions: C4BP, an important fluid-phase inhibitor of the classical and lectin pathway of complement activation binds to
jeopardized cardiomyocytes early after AMI and co-localizes to other well known markers such as C3b.
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Introduction
During the course of several cardiovascular events cell death
occurs [1]. The presence of dead cells not only impairs the
function of tissues but also forms a rich source of inflammatory
mediators and autoantigens [2–4]. Acute myocardial infarction
(AMI) is one of the major causes of mortality and morbidity in the
western world. Arrhythmia, cardiac rupture and acute heart
failure comprise the main events leading to mortality whereas
chronic heart failure is the leading cause for morbidity. If the
myocardium is deprived of perfusion for several hours, prolonged
ischemia results in permanent loss of function through cell death
by apoptosis [5,6]. In case reperfusion is achieved within this time
frame than the extent of cell death is limited [7]. However,
reperfusion as such is not just beneficial but may also have adverse
effects. Cells suffer from this reperfusion, which may lead to
irreversible injury, thought to occur via apoptosis and inflamma-
tion related necrosis [8]. Complicated interactions, between
ischemic or dead cardiomyocytes and inflammatory cells,
cytokines, acute phase proteins and complement components
result in the pathologies observed in AMI [9]. The involvement of
the complement system in AMI has been concluded from both
animal models and human studies where the affected areas in the
heart stained positive for several complement components,
including C1q, mannose-binding lectin, C3 and C5b-9. Based
on these and other observations it was concluded that all three
pathways of complement activation participate in the process.
Although the complement system often contributes to the tissue
damage it is not easy to discriminate this from the beneficial effects
of complement in terms of waste disposal.
C-reactive protein (CRP) is an acute phase protein in humans
and it was reported to be (in part) responsible for the complement
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activation in AMI [10–12]. CRP constitutes a strong cardiovas-
cular risk factor since its plasma levels in both healthy individuals
and in patients correlate with occurrence of AMI and are also
predictive for the progression of disease once AMI occurs [13].
CRP has been reported to activate the classical pathway of
complement by binding C1q [14]. Indeed CRP has been shown to
be co-localized to these areas of the heart that are positive for
complement deposits [10]. CRP may bind to dead cardiocytes via
lyso-phosphatidylcholine that is generated from phosphatidylcho-
line by phospholipase A2 [5]. We have recently shown that cell
death by itself carries the potential to activate the complement
system, both in the presence or absence of CRP [15]. The
complement system has very powerful effects and is therefore kept
under control by both membrane bound and soluble complement
inhibitors. We have shown previously that one of these fluid-phase
complement inhibitors, C4b-binding protein (C4BP) binds to dead
cells and provides protection against excessive complement
activation [16–18]. Also by binding DNA on and released from
dead cells it inhibits an inflammatory responses [16]. C4BP is
present in serum mostly as a complex with anti-coagulant protein
S (C4BP-PS) [19] bound to a beta-chain that together with seven
alpha-chains forms one C4BP molecule. Protein S has a high
affinity for negatively charged phospholipids and is the module of
the C4BP-PS complex that is responsible for most of the binding to
apoptotic and necrotic cells. The alpha-chains contain the
complement inhibitory capacity and present activated comple-
ment components C4b and C3b to factor I for degradation. These
alpha-chains also contain the DNA binding site [16].
In the current study we have investigated whether C4BP binds
to compromised cardiomyocytes in relation to cardiovascular
events. Here we describe that C4BP forms deposits in the heart in
several cardiovascular diseases, but based on both the intensity of
depositions and the frequency of positivity it is mostly observed in
AMI. In AMI lesions it is correlated to areas also positive for C3b.
Binding of C4BP to cardiomyocytes peaks, like C3b, between
12 hours and 5 days after the infarction, during the phase in
which infiltration of neutrophilic granulocytes in the heart is the
most extensive.
Materials and Methods
Patients
Samples were obtained from patients who had died following
cardiovascular events and were collected in line with the
institutional guidelines of the VU Medical Center in Amsterdam,
The Netherlands. These patients had given their written informed
consent for the use of tissue material for research purposes. The
tissue array samples were collected in line with the Lund
University ethical comity decision LU-232-01, Lund University,
Lund, Sweden, both in accordance with the Helsinki declaration.
Tissue arrays were generated from heart samples patients
suffering from AMI, hypertrophy and aorta stenosis. The samples
for the tissue arrays were selected based on detailed evaluation of the
autopsy reports followed by clinical and histological confirmation.
Aorta stenosis, a condition that results in pressure overload induced
myocardial hypertrophy, was based on clinical and morphological
data (confirmed at autopsy). The hypertrophy group was selected
based on increased myocardial mass. This is a heterogeneous group
with hypertrophy caused by several underlying conditions including
arterial hypertension, ischemic heart disease and left sided valvular
leaks with potential overlap between the conditions. We excluded
hearts with suspected obstructive hypertrophic cardiomyopathy.
In a separate study tissue samples were stained histochemically
allowing correlation between positivity of C4BP and the stage of
AMI as well as presence of C3b determined by immunohisto-
chemistry. Three areas were identified in AMI patients: (A) the
infarcted area, based on lactate dehydrogenase decolourization,
(B) the border zone, right next to A and (C) non affected, remote
areas of the same heart.
For quantitative studies samples were grouped according to time
after infarction. Group I, n = 9, infarction of 4–12 hours (lactate
dehydrogenase decolourization, no influx of neutrophilic granu-
locytes), Group II, n = 9, infarction of 12 hours–5 days old (acute
inflammatory phase), Group III, n = 4, infarction 5–14 days old
(chronic inflammatory phase).
Immunohistochemistry
Paraffin embedded tissue in the form of tissue arrays were
deparaffinized using routine procedures and samples were stained
for C4BP as described [16]. For quantitative studies in AMI
paraffin embedded tissue sections (4 mm thick) were mounted on
microscope slides and deparaffinized for 10 minutes in xylene at
room temperature and dehydrated through descending concen-
trations of ethanol. One set of sections was stained with
hematoxylin and eosin using routine procedures. Endogenous
peroxidase activity was blocked by incubation in 0.3% (v/v) H2O2
in methanol for 30 minutes. Tissue sections were subjected to
antigen retrieval by boiling in 10 mM sodium citrate buffer, pH 6,
for 10 minutes in a microwave oven. All antibodies and normal,
pre-immune serum were diluted in PBS containing 1% (w/v)
bovine serum albumin (BSA). Tissue sections were pre-incubated
for 10 minutes with normal swine serum, followed by incubation
for 1 hour with C4BP antibodies. The antibodies were raised in
rabbits against highly purified human C4BP-PS complex (kind gift
from Prof. Dahlba¨ck, Lund University, Sweden). The antibodies
from rabbit serum were first purified using protein A and protein
G columns (GE Healthcare) coupled in tandem followed by
affinity purification using a column (Affi-gel 10, Biorad) with
covalently coupled human C4BP-PS. After washing in PBS tissue
sections were incubated for 30 minutes with a biotin-conjugated
swine anti-rabbit secondary antibody (DAKO). After washing in
PBS slides were incubated with streptavidin–biotin complex
(DAKO) for 1 hour. After the incubation with streptavidin–biotin
complex C4BP was visualized with 3,39-diaminobenzidine
(0.1 mg/ml, 0.02% H2O2). Staining for deposition of C3b was
performed using mouse mAb C3-15 (kind gift from Prof Hack,
The Netherlands) which recognizes the C3d fragment of C3b
exactly as described previously [10]. Additional stainings were
performed using goat anti-C4 and goat anti-C9 polyclonal
antibodies (Quidel) with matched secondary antibodies (DAKO).
Slides were counterstained with hematoxylin and mounted with
Depex (VWR International).
Samples were analyzed semi-quantitatively in order to discrim-
inate between the several cardiovascular disorders. Samples were
graded as: +/2, negative/background positive for C4BP, ++,
positive and +++, strongly positive. In addition AMI samples were
analyzed quantitatively for the area of positivity/tissue slide by
computer-assisted morphometry (QPRODIT).
Cells, proteins and treatments
Neonatal rat cardiomyoblasts, H9C2 cells (ATCC) were cultured
as before [20]. Briefly, cells were grown at 37uC in 5% CO2 in
Dulbecco’s modified Eagle’s medium supplemented with 10%
(vol/vol) heat-inactivated fetal calf serum, 100 IE/ml sodium
penicilline, 100 mg/L streptomycin, and 2 mM L-glutamine, all
from Invitrogen. For experiments cells grown to a confluency of
60–80% were used. Cells were detached from the culture flasks
using versene (Invitrogen). Cells were either analyzed as live cells
C4BP in Cardiovascular Disease
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or were induced into apoptosis by incubating with staurosporine at
0.5 mM for 15 hours at 37uC or induced into necrosis by
incubating the cells at 56uC for 30 minutes in RPMI without
FCS. Cell death was confirmed by flow cytometry using Annexin
V and Via-Probe staining (BD Biosciences). Alternatively, H9C2
cells were exposed to 3 hours of acute hypoxia (0.1% oxygen)
followed by 1 hour of reoxygenation. To achieve hypoxic
conditions, cells were kept in a humidified hypoxia chamber, the
Hypoxia Workstation 400 (Ruskinn Technology), connected to a
Ruskinn gas mixer module supplying 95.9% N2, 5% CO2 and
0.1% O2. Normoxic or hypoxic cells were incubated with C4BP-
FITC or prothrombin-FITC both at 0.1 mg/ml and binding was
analyzed by flow-cytometry. The C4BP-PS complex [21] and
prothrombin [16] were purified from normal human plasma and
labeled with FITC as described before. The mean fluorescence
intensity (MFI) of C4BP-FITC was normalized to the MFI of
prothrombin-FITC, used here as a negative control and the ratios
for independent experiment (n = 4) were averaged and expressed
as means +/2 standard deviation (SD).
Flow cytometry
Binding of C4BP to cardiomyocytes was analyzed by flow
cytometry. Following washing cells were incubated with increasing
concentrations of purified human C4BP-PS (0–25 mg/ml) diluted
in binding buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl,
1 mM MgCl2, 1.8 mM CaCl2), for 30 minutes at room temper-
ature. Following washing with binding buffer cells were incubated
with a rabbit anti-human C4BP antibody, followed after washing
with swine anti-rabbit FITC labeled antibodies (DAKO). The cells
were analyzed using FACS Calibur (BD Biosciences).
Statistical analysis
Data analysis was performed with GraphPad Prism software.
The data were normally distributed and Student’s t-test was used
to calculate the significance of the differences. A p value (two
tailed) of less than 0.05 was considered to be significant.
Results
C4BP deposition occurs in several cardiovascular diseases
but is strongest in AMI
By using tissue arrays of several cardiovascular diseases we set
out to determine if C4BP deposition occurred in cardiac disease.
We have compared samples from patients diagnosed with cardiac
hypertrophy, aorta stenosis and AMI. The healthy parts of patient
heart tissue showed only very modest C4BP positivity, which
appeared not to be cell associated and may reflect C4BP present in
blood (Figure 1). C4BP immunostaining was relatively weak in
aorta stenosis and hypertrophy with some staining on individual
cardiomyocytes and of the space between the cells (Figure 1). In
contrast, in AMI a strong staining of C4BP was observed on all
cardiocytes in the entire region. By semi quantitative scoring of the
intensity of staining of those tissue arrays we observed that both
the frequency and the positivity for C4BP were highest in AMI
compared to hypertrophy and aorta stenosis (Figure 1B). Based on
these results we focused further experiments on AMI.
C4BP is deposited on affected cardiomyocytes
In AMI heart tissue C4BP localization was limited mostly to
jeopardized cardiomyocytes (Figure 2). Depending on the angle of
cutting, the sections displayed a banded pattern on the
cardiomyocyte (Figure 2C, D). The positive staining of the
myofiber elements included the sarcolemma, cytoplasm and
cross-striation. While in some cases there was a gradual change
in intensity of the C4BP positivity (Figure 1A), in other cases there
was a sharp boundary between positive and negative areas
(Figure 2A). In fact, at a higher magnification it is possible to see
adjacent cells of which one is positive and the other is negative for
C4BP (Figure 3A), indicating that the cell needs to go over a
certain threshold of changes before it binds C4BP.
C4BP positivity extends beyond positivity for C3b
To test if the localization of C4BP is related to the affected area,
samples were stained for the presence of C3b and analyzed by
computer assisted scoring of area of positivity. Based on several
morphological criteria as well as patient records it was possible to
estimate the time after occlusion and to relate the findings of C4BP
and C3d intensity to the time after infarction. The positivity for
C4BP and C3b was scored in the infarcted area, the area just
adjacent to this ( = border zone area) and in remote areas. Indeed
Figure 1. C4BP is present on compromised heart tissue. (A)
Tissue arrays of heart tissue from patients suffering from aorta stenosis,
hypertrophy and AMI were stained with hematoxylin and eosin or for
C4BP. Representative examples are shown. Original magnification 1006.
(B) Semiquantitative analysis of the percent of cases subgrouped for the
intensity of C4BP staining.
doi:10.1371/journal.pone.0002886.g001
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positivity for C4BP was mainly observed in the areas with
extensive cell death, but it was also found on locations in the
border zone and even the non-affected tissue (Figure 3A, B).
Staining of consecutive sections for C3b revealed that C4BP was
located to similar areas as C3b except for the areas in the non-
affected tissue.
Both C4BP and C3b were not present in samples of very early
infarction samples but both were deposited during the acute
inflammatory phase (12 hours to 5 days old). C3b positivity
diminishes after this period, while C4BP stays positive over a more
prolonged period of time. The fact that C4BP was observed in the
adjacent tissue while C3b was not deposited there, could indicate that
C4BP present on this location is sufficient to protect against
complement activation and deposition of C3b on the adjacent tissue.
The pattern of staining of microscopical infarction areas for
C3b, were identical to IgM and CRP [22]. In these larger
infarction areas C4BP had the same staining pattern as C3b, but
interestingly also stained individual cardiomyocytes, that were
morphologically normal beyond that microscopical area
(Figure 3B, C).
Sections were also stained for C4 and C9, as a marker for
deposition of the membrane attack complex, and we observed that
deposition of C4 and C9 peaks during the acute inflammatory
phase, just as is the case for C3b and C4BP (data not shown).
By staining consecutive sections for the presence of C4, C3b, C9
and C4BP we observed that both C4 and C9 are present on the
affected tissue in a similar pattern as C3b (figure 4A). Collectively
these data indicate that complement is activated on the affected
heart tissue, including deposition of C4 and C3b up to the
formation of the membrane attack complex and that C4BP, which
is deposited strongly in the affected and weakly in the close
Figure 2. C4BP binds to individual cardiomyocytes. Compro-
mised cardiomyocytes stain positive for C4BP shown in both cross
sectional (A,B) and sagital view (C, D). Boxed areas in A and C (original
magnification 1006) are shown at higher magnification in B and D
(original magnification 4006). Arrowhead in D shows cross-striation,
typical for cardiomyocytes.
doi:10.1371/journal.pone.0002886.g002
Figure 3. Binding of C4BP is strongest during the acute inflammatory phase of AMI and correlates to C3b. (A) Consecutive sections
were stained for C4BP and C3d and display binding to the same area of compromised heart tissue (original magnification 506). Higher magnification
pictures of the same area show individual cardiomyocytes positive for both C3d and C4BP (original magnification 4006). Arrows indicate positive
cardiomyocytes. (B) Quantification of the % of positive area for C4BP in the infracted area, the adjacent area or remote areas during the early, acute
inflammatory or chronic inflammatory phase of AMI. (C) Quantification of the % positive area for C3b on the same locations and time points.
doi:10.1371/journal.pone.0002886.g003
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unaffected area, could function as a protective factor by inhibiting
excessive complement activation.
Cultured cardiomyocytes bind C4BP mainly following cell
death
As a model for human cardiocytes we have used rat
cardiomyocyte cell line H9C2. These cells were cultured in vitro,
harvested and rendered apoptotic by addition of staurosporine, or
necrotic by incubating in heat (30 minutes, 56uC). Live, late-
apoptotic and necrotic cells (as determined by staining with
annexin V and Via-probe) were incubated with increasing
concentrations of purified C4BP-PS and the binding was analyzed
by flow cytometry. C4BP-PS displayed a background binding to
live cardiomyocytes but binding of C4BP-PS was increased in a
dose-dependent manner on apoptotic and especially necrotic cells
(Figure 5A). These data indicate that cell-death is one of the
mechanisms by which C4BP binds to the heart tissue. In addition
to cell death we have also analyzed the binding of C4BP to H9C2
cells cultured in hypoxic conditions. The binding of C4BP to
normoxic H9C2 cells is low and increased only marginally on the
hypoxic cells (Figure 5B). Under these conditions of hypoxia we
did not observe apoptotic or necrotic H9C2 cells as determined by
staining for annexin V and Via-probe (not shown).
Discussion
C4BP, the main fluid-phase inhibitor of the classical and lectin
pathway of complement activation is present in affected tissue of
patients suffering from AMI. C4BP was shown previously to bind
to dead cells and provide protection against excessive complement
activation and inflammation otherwise evoked by these cells [15–
18]. C4BP as a complement inhibitor limits complement
activation but does not provide a complete block [19]. Indeed
this is what we also observed in the current study, C4BP co-
localizes with C4, C3b and C9 in the damaged heart tissue, which
indicates that in the presence of C4BP there is still complement
activation, but it would have been much more extensive if C4BP
was lacking as we have shown previously for other cell types [16].
The observation that C4BP is found on the surrounding tissue in
the absence of C3b may indicate that the levels of complement
inhibition by C4BP are sufficient there to protect against
complement activation but not in the larger infarct areas. To
firmly establish the relative importance of C4BP in these lesions
one would have to use animal models of AMI, using C4BP
deficient animals.
Although the complement system contributes to the tissue
damage it is not easy to discriminate this from the beneficial effects
of complement in terms of waste disposal. Nonetheless, experi-
Figure 4. C4, C3b and C9 are also present on the affected tissue. Representative pictures of consecutive sections of heart tissue of an AMI
sample stained for C4, C3b, C9 and C4BP or with secondary antibody only (PBS).
doi:10.1371/journal.pone.0002886.g004
Figure 5. C4BP binds strongly to dead but not live cardiomyocytes. (A) Rat cardiomyocyte cell line H9C2 was used to study the binding of
human C4BP to live, apoptotic or necrotic cardiomyocytes. Binding of C4BP to these cells was analyzed by FACS and is displayed as mean
fluorescence intensity (MFI). Increasing concentrations of C4BP lead to increased binding to apoptotic and especially necrotic cardiomyocytes with no
binding to live cells. (B) Slightly enhanced binding of C4BP to hypoxic H9C2 cells compared to normoxic. The MFI of C4BP-FITC was normalized to the
MFI of prothrombin-FITC, used as a negative control and the ratios for independent experiment (n = 4) were averaged and expressed as means +/2
SD.
doi:10.1371/journal.pone.0002886.g005
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ments using complement deficient animals and complement
inhibiting drugs revealed reduced infarction size in the absence
of complement activation indicating that complement does
contribute to pathology (reviewed by [9]). Complement activation
can have several effects on the infarcted heart, e.g. lysis of cells by
means of the membrane attack complex, release of C5a that
attracts neutrophils but it can also influence the function of the
myocardium itself. Several studies have found activated comple-
ment components on myocardium especially after sufficient time
of infarct duration of more than 12 hours [10,23].
Both C4BP and factor H have been reported to play a role in
cardiovascular disease such as atherosclerosis. C4BP is present and
inhibits classical pathway activity in atherosclerotic lesions [24]
and in the necrotic areas of advanced atherosclerosis [16]. Factor
H has also been located in atherosclerotic lesions and has been
implicated as a protective factor [25]. In the atherosclerotic
plaques synthesis of complement factors is upregulated but not
that of complement inhibitors [26] indicating that most likely the
inhibitors are localized there from blood.
Both C3b and CRP have been observed in the same binding
pattern as C4BP, with a cytoplasmic staining and cross-striation
[10]. This may indicate that these proteins are in fact located both
on the outside and on the inside of these cells. For CRP it was
reported that it does not stain nuclear elements and it seems that
also C4BP staining does not reveal a staining for nuclear elements,
which is interesting since both CRP and C4BP are reported to
bind DNA. The binding of C4BP to dead cells in the heart tissue
may be easily explained by the binding of the C4BP-PS complex
to phosphatidylserine, as we reported before for other cell types
[16–18]. However, the binding of C4BP to seemingly healthy
tissue surrounding the dead area is less clear, either these cells have
undergone a certain extend of membrane reorganization or flip-
flop that allows the binding of the C4BP-PS complex. Another
possibility would be that hypoxic cells show increased binding of
C4BP but we only observed a small increase in C4BP binding at
high C4BP concentrations. However, it is clear that C4BP binding
in these areas is not dependent on its ligands complement C4b and
C3b since they are absent from these areas.
To our knowledge C4BP has not been used to treat or prevent
pathology in the context of cardiovascular disease, whereas supra-
normal levels of C4BP may provide a relatively safe approach.
Clearly more studies are needed before such experimentation can
be translated into a clinically useful approach.
In conclusion: in this study we provide evidence that fluid-phase
complement inhibitor C4BP binds to compromised heart tissue.
The deposition is strongest in AMI compared to aorta stenosis and
ischemic heart disease and it takes place during the inflammatory
phase of AMI. C4BP positivity extends beyond the area positive
for C3b, which suggests that C4BP is a functional complement
inhibitor in AMI and limits complement activation to the most
affected tissue.
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